Clinical trials: PDAC, open to volunteers
Pancreatic Cancer, Pancreatic Neoplasms
Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens
The goal of this clinical study is to evaluate whether the NEO-Match® test, based on ARTIDIS nanomechanical profiling technology, can help predict treatment outcomes and improve clinical decision-making in patients with suspected…
- Conditions
- Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Lesions Located at the Body or the Tail
- Trial name
- ANoPs (NCT07542041)
- Testing
- ARTIDIS ART-1 Device
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- ARTIDIS AG
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
The Use of Contrast Enhanced Ultrasound (CEUS) In Post-Surgical Pancreatic Cancer Patients to Evaluate Local Disease Recurrence
This pilot study is testing whether a special type of ultrasound called contrast-enhanced ultrasound (CEUS) can help detect if pancreatic cancer has come back after surgery.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Local Disease
- Trial name
- NCT07910383
- Testing
- Lumason, Contrast-Enhanced Ultrasound
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Thomas Jefferson University
Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)
The investigators are developing a non-invasive breath test to help us detect pancreatic cancer earlier. The test detects small molecules called volatile organic compounds that are made by pancreatic cancers.
- Trial name
- NCT07243262
- Testing
- Breath test
- Where
- United Kingdom
- Volunteers
- 6,079 people
- Sponsor
- Imperial College London
Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Pancreatic ductal adenocarcinoma (PDAC)
- Trial name
- NCT07301229
- Testing
- HLX43 DOSE 1 (2.5 mg/kg), HLX43 DOSE 2 (3.0 mg/kg)
- Volunteers
- 100 people
- Sponsor
- Shanghai Henlius Biotech
Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced and Metastatic Pancreatic Cancer
NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer
This study aims to evaluate the safety and preliminary efficacy of NALIRIFOX combined with adebrelimab and PULSAR as first-line treatment for locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC).
- Trial name
- NCT07595172
- Testing
- NALIRIFOX+Adebrelimab, PULSAR
- Where
- China
- Volunteers
- 55 people
- Sponsor
- West China Hospital
Pancreatic Ductal Adenocarcinoma (PDAC)
RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer
PDAC (Pancreatic ductal adenocarcinoma) represents 90% of pancreatic tumors. The prognosis of PDAC remains poor at this time. Its management is based on surgery for early stages, associated with neoadjuvant and adjuvant…
- Trial name
- PaCaBioMarkeR (NCT04575363)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 90 people
- Sponsor
- CHU de Reims
Advanced Solid Tumor, PDAC
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for…
- Conditions
- Advanced Solid Tumor, PDAC, HNSCC
- Trial name
- NCT06597721
- Testing
- ADCE-T02
- Where
- 14 sites in United States, Australia
- Volunteers
- 210 people
- Sponsor
- Adcendo ApS
Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 Combined with Chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma…
- Trial name
- NCT07235202
- Testing
- MR001, Irinotecan Liposome Injection combined with 5-FU/LV, Nab-paclitaxel
- Where
- 18 sites in China
- Volunteers
- 45 people
- Sponsor
- Shenzhen Majory Biotechnology Co., Ltd.
Pancreatic Ductal Adenocarcinoma (PDAC)
European Appleby Registry for Pancreatic Cancer
The EURO-APPLEBY Registry is a prospective, multicenter European observational registry designed to characterize contemporary surgical practice and evaluate perioperative and long-term oncological outcomes in patients undergoing…
- Trial name
- EURO-APPLEBY (NCT07889180)
- Volunteers
- 100 people
- Sponsor
- Institut Investigacio Sanitaria Pere Virgili
Pancreatic Ductal Adenocarcinoma (PDAC)
A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
This study will enroll adults with confirmed metastatic pancreatic ductal adenocarcinoma (PDAC, systemic PDAC treatment naïve), Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, and adequate organ function.
- Trial name
- NCT07255404
- Testing
- Pumitamig, Nab-paclitaxel, Gemcitabine
- Where
- 24 sites in Australia, China
- Volunteers
- 105 people
- Sponsor
- BioNTech SE
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
- Conditions
- Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
- Trial name
- NCT06835569
- Testing
- ALTA3263, cetuximab, mFOLFOX6
- Where
- 14 sites in United States
- Volunteers
- 448 people
- Sponsor
- Alterome Therapeutics, Inc.
Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy
The purpose of this study is to evaluate the safety and efficacy of an investigational B7-H3 antibody drug-conjugate administered as monotherapy, compared with standard of care (SOC) chemotherapy in metastatic pancreatic cancer…
- Trial name
- NCT07803783
- Testing
- Tambotatug pelitecan, Liposomal irinotecan, 5 Fluorouracil
- Where
- China
- Volunteers
- 320 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Pancreatic Adenocarcinoma, Pancreatic Intraepithelial Neoplasia
The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma
Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic cancer and its noninvasive precancerous lesions.
- Trial name
- NCT06157671
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Adenocyte, LLC
Diabetes, IPMN, Pancreatic
Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g.
- Conditions
- Diabetes, IPMN, Pancreatic, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- LASERBLOOD (NCT07659639)
- Testing
- Diagnostic procedures
- Where
- Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Campus Bio-Medico